Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R Domain
Authors:
- Stamatia C. VorriSVStamatia C. Vorri
- Natalie J. HollNHNatalie J. Holl
- Michael LeemingMLMichael Leeming
- Petya ApostolovaPAPetya Apostolova
- Andrew MarpleAMAndrew Marple
- Jonas W. RavichJRJonas W. Ravich
- Ata CanbazACAta Canbaz
- Ruyan RahnamaRRRuyan Rahnama
- Jun ChoeJCJun Choe
- Arjun ModiAMArjun Modi
- Adam D. FearnowAFAdam D. Fearnow
- Scott T. R. WalshSWScott T. R. Walsh
Open Access
- 1 September 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 4 (9) , 2359-2373
Abstract
Chimeric antigen receptor (CAR) T cells can effectively treat leukemias, but sustained antitumor responses can be hindered by a lack of CAR T-cell persistence. Cytotoxic effector T cells are short-lived, and establishment of CAR-T cells with memory to ensure immune surveillance is important. Memory T cells depend on cytokine support, with IL7 activation of the IL7 receptor (IL7R) being critical. However, IL7R surface expression is negatively regulated by exposure to IL7. We aimed to support CAR T-cell persistence by equipping CAR-T cells with a sustained IL7Rα signal. We engineered T cells to constitutively secrete IL7 or to express an anti–acute myeloid leukemia–targeted IL7Rα–chimeric cytokine receptor (CCR) and characterized the phenotype of these cell types. Canonical downstream signaling was activated in CCR-T cells with IL7R activation. When coexpressed with a cytotoxic CAR, functionality of both the CCR and CAR was maintained. We designed hybrid CAR–CCR and noted membrane proximity of the intracellular domains as vital for signaling. These data show cell-intrinsic cytokine support with canonical signaling, and functionality can be provided via expression of an IL7Rα domain whether independently expressed or incorporated into a cytotoxic CAR for use in anticancer therapy. Significance: To improve the phenotype of tumor-directed T-cell therapy, we show that provision of cell-intrinsic IL7R-mediated signaling is preferable to activation of cells with exogenous IL7. We engineer this signaling via independent receptor engineering and incorporation into a CAR and validate maintained antigen-specific cytotoxic activity.Keywords
All Related Versions
This publication has 62 references indexed in Scilit:
- IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory CellsJournal of Immunotherapy, 2006
- Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell poolJournal of Clinical Investigation, 2005
- IL-7: maintaining T-cell memory and achieving homeostasisTrends in Immunology, 2005
- Labeling of fusion proteins with synthetic fluorophores in live cellsProceedings of the National Academy of Sciences, 2004
- IL-7 Promotes the Transition of CD4 Effectors to Persistent Memory CellsJournal of Experimental Medicine, 2003
- Cytokine control of memory T-cell development and survivalNature Reviews Immunology, 2003
- A general method for the covalent labeling of fusion proteins with small molecules in vivoNature Biotechnology, 2002
- Overexpression of Interleukin (IL)-7 Leads to IL-15–independent Generation of Memory Phenotype CD8+ T CellsJournal of Experimental Medicine, 2002
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivoNature Immunology, 2000